@cnag-eu.bsky.social💛 𝗧𝗼𝗺𝗼𝗿𝗿𝗼𝘄 𝗶𝘀 #WorldCancerResearchDay
At CNAG, we couldn’t be more committed to cancer research: we study mutations, help identify therapeutic targets and analyse how tumours evolve.
🧬 Because cancer is a disease of the genome
#CancerResearch #Genomics #Cancer #InvestigacióndeCancer #RecercaCàncer
@gmj-georgia.bsky.socialAfter 30 years, scientists have finally solved the structural mystery of two molecules in rye pollen that showed anti-tumour activity in animal studies. Th… #Cancerresearch #Drugdiscovery #Immunology #Molecularstructure #Naturalproducts #Cancerresearch #Drugdiscovery #Immunology #Molecularstruc…
@sebastienja.bsky.socialVery pleased to see our work highlighted by the Institut de Recherche Saint-Louis
Our Molecular Therapy study identifies miR-Comb-15, a 15-miRNA combination with antitumor activity in aggressive cancer
institut-recherche-saint-louis.fr/une-nouvelle...
#ExtracellularVesicles #microRNA #CancerResearch
@sinclaircri.bsky.socialToday at 3PM: seminar with @dyrskjot.bsky.social (Aarhus Univ), hosted by our CBG division's Dr. Madhuri Koti @sinclaircri.bsky.social. Drop in — everyone welcome. Info/questions: [email protected] #BladderCancer #ctDNA #CancerResearch
@crcm.bsky.social📣 External Seminar
Alexis Combes from the University of California (San Francisco, United States), will talk about the links between tissue immunity, cancer, and inflammation.
📍CRCM Library
📆 September 30, 2026
🕘 2:30 PM
@lsajournal.orgNew research shows that an N-terminal dTAG cassette alters RAF1 scaffold function in KRAS-driven lung cancer models before degradation, underscoring the importance of validating tagged proteins.
#CancerResearch #TPD
www.life-science-alliance.org/content/9/12...
@bcc2026.bsky.socialHave new findings or expertise in breast cancer research?
Interested in speaking at #BreastCancerCongress2027?
Want to present your research?
Zurich, Switzerland| June 17–18,2027
Speaker Request: pinkribboncongress.com/request-spea...
#BreastCancer #Oncology #CancerResearch #MedicalResearch #BCC
@edwardsdna.bsky.socialExceptional Detection Rates of Bladder Cancer Recorded in Study of Simple, Yet State-of-the-Art Test: An observational study in the UK has just produced substantially positive results for a… @goodnewsnetwork.org #BladderCancer #CancerResearch #HealthInnovation #NonInvasiveTesting #GeneticTesting
@gmj-georgia.bsky.social🔬 ETH Zurich scientists have designed a light-controlled molecular switch that wakes dormant cancer cells and makes them vulnerable… #Cancerresearch #Dormantcancercells #Optogenetics #Precisiononcology #Treatmentresistance #Cancerresearch #Dormantcancercells #Optogenetics #Precisiononcology #Tr…
@eaonc.bsky.socialDecades of federal investment in #CancerResearch have saved millions of lives. American Association for Cancer Research (AACR)'s Cancer Progress Report asks Congress to sustain NIH/NCI funding & protect grants from interference—because progress against #cancer depends on it. https://bit.ly/4xC3bRk
@dralhilali.comWhat happens when cancer specialists from around the world meet?
At #ISDE2026 in Kyoto, specialists shared research, challenged current practice and compared approaches - all with the aim of improving how we care for patients.
@gih.geScotland’s cancer frontier is evolving — from personalised vaccines to AI-powered screening and precision medicine. Discover how research and innovation are shaping the future of cancer care.
@jmarchitects.bsky.socialA Morning of Coffee, Cake & Charity! ☕🧁
#jmarchitects #wearejmarchitects #jma #architecture #design #construction #news #architects #community #charity #coffeemorning #Macmillan #cancerresearch #donation #cakes #coffee
@essexindustries.bsky.socialThe Essex team completed the Pedal the Cause 2026 ride, marking our 8th year riding together! We raised a personal record of $19,150 for cancer research this year, bringing our lifetime total to $51,607!
Donate here:
www.givesignup.org/Race/157721/...
@islb.infoHow is Europe moving liquid biopsy into routine care?
At #ISLB2026, leaders from PREDI-LYNCH, SPARC, JA-PCM & GUIDE.MRD will explore clinical validation, MRD monitoring and equitable implementation across Europe.
𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞 & 𝐫𝐞𝐠𝐢𝐬𝐭𝐞𝐫 → islb-congress.info
@thecancersurvivorsclub.comEncouraging results in HER2-mutant lung cancer. Enhertu achieved median progression-free survival of 14.3 months versus 8.3 months with chemotherapy plus immunotherapy in DESTINY-Lung04.
@exo-beyondthecell.bsky.socialNew Podcast Episode Out Now!
Can exercise do more than improve fitness? Can it help us discover new cancer therapies?
Listen to the conversation:
🔗 sciexplor.com/exo/podcast/6
Also now streaming on:
YouTube: youtu.be/zLwOQxEtBq0
Spotify: open.spotify.com/episode/7gta...
#CancerResearch #Exercise
@fgbonadonna.bsky.socialResults from BREAKWATER Cohort 3 trial show clinically meaningful improvements in objective response rate and progression-free survival for encorafenib, cetuximab plus FOLFIRI in BRAF V600E-mutant colorectal cancer
fondazionebonadonna.org/en/encorafen...
#FondazioneBonadonna #CancerResearch
@eortc.orgThe latest @qol.eortc.org annual newsletter is out, showcasing recent advances in quality of life research, Group activities, and collaborations across the EORTC network.
Read more: qol.eortc.org/newsletters/...
@trail4l.bsky.socialNew findings on the non-lethal functions of cell death proteins highlight their roles in cancer progression, signalling and immunosuppression—closely aligning with the concepts explored by TRAIL4Life.